Literature DB >> 5052904

Comparative bioavailability of three brands of ampicillin.

C MacLeod, H Rabin, J Ruedy, M Caron, D Zarowny, R O Davies.   

Abstract

The relative biological availability (bioavailability) of three brands of ampicillin trihydrate capsules marketed in Canada was studied by means of a crossover experimental design and was evaluated by analysis of variance. After administration of a single oral dose (500 mg.) to volunteer subjects, the mean peak ampicillin serum concentration and the area under the time ampicillin serum concentration curve (AUC) were higher for one of the products than for the other two. A second study utilizing the same experimental design revealed no differences in these parameters when different production lots of the more available product were compared. Product bioavailability was not related to the in vitro dissolution time of the capsules. The experimental design and methods of statistical analysis are discussed.

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 5052904      PMCID: PMC1940893     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN: 0008-4409            Impact factor:   8.262


  7 in total

1.  Simplified, accurate method for antibiotic assay of clinical specimens.

Authors:  J V Bennett; J L Brodie; E J Benner; W M Kirby
Journal:  Appl Microbiol       Date:  1966-03

2.  In vivo and in vitro availability of commercial warfarin tablets.

Authors:  J G Wagner; P G Welling; K P Lee; J E Walker
Journal:  J Pharm Sci       Date:  1971-05       Impact factor: 3.534

3.  Variation in biologic availability of digoxin from four preparations.

Authors:  J Lindenbaum; M H Mellow; M O Blackstone; V P Butler
Journal:  N Engl J Med       Date:  1971-12-09       Impact factor: 91.245

4.  Status report on drug bio-availability.

Authors:  G H Schneller
Journal:  Am J Hosp Pharm       Date:  1970-06

5.  The physiologic availability of solid dosage forms of phenylbutazone. II. Correlation of in vivo physiologic availability and in vitro dissolution parameters.

Authors:  R J Withey; H Feng; D Cook; G R Van Petten; H F Lettau
Journal:  J Clin Pharmacol New Drugs       Date:  1971 May-Jun

6.  The physiologic availability of solid dosage forms of phenylbutazone. I. In vivo physiologic availability and pharmacologic considerations.

Authors:  G R Van Petten; H Feng; R J Withey; H F Lettau
Journal:  J Clin Pharmacol New Drugs       Date:  1971 May-Jun

7.  Assessment of the biologic availability of tetracycline products in man.

Authors:  W H Barr; L M Gerbracht; K Letcher; M Plaut; N Strahl
Journal:  Clin Pharmacol Ther       Date:  1972 Jan-Feb       Impact factor: 6.875

  7 in total
  7 in total

1.  Comparative bioavailability.

Authors:  R Barr; N Eade; C Marchant; C Oliver; E Petsonk; N Steinmetz
Journal:  Can Med Assoc J       Date:  1972-11-04       Impact factor: 8.262

2.  Rapid, precise, turbidometric assay for low levels of ampicillin in serum after single-dose oral administration.

Authors:  P L Whyatt; R E Dann; G W Slywka; M C Meyer
Journal:  Antimicrob Agents Chemother       Date:  1974-12       Impact factor: 5.191

3.  Bioavailability.

Authors:  W T Clarke
Journal:  Can Med Assoc J       Date:  1973-04-21       Impact factor: 8.262

4.  Comparative bioavailability.

Authors: 
Journal:  Can Med Assoc J       Date:  1972-11-04       Impact factor: 8.262

5.  Bioavailability of 11 phenytoin products.

Authors:  A P Melikian; A B Straughn; G W Slywka; P L Whyatt; M C Meyer
Journal:  J Pharmacokinet Biopharm       Date:  1977-04

6.  Relative bioavailability of commercial ampicillin formulations in man.

Authors:  M Mayersohn; L Endrenyi
Journal:  Can Med Assoc J       Date:  1973-11-17       Impact factor: 8.262

7.  Epidermolysis bullosa dystrophica treated with vitamin E and oral corticosteroids.

Authors:  W P Unger; J R Nethercott
Journal:  Can Med Assoc J       Date:  1973-05-05       Impact factor: 8.262

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.